12/28/2023 0 Comments Foresight diagnosticsAt Stanford she specialized in the treatment of lymphomas, authoring more than 150 studies and participating in over 50 clinical trials, including multiple studies involving MRD.ĭr. Horning was a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University for more than 20 years, where she remains a Professor Emerita. Previously, she served at Genentech/Roche as Chief Medical Officer and Head of Global Product Development from 2014 to 2019, where she oversaw the approval of 15 new medicines for multiple disease areas, including B-cell lymphomas. Horning is a co-founder and board member of EQRx and currently serves on the Boards of Directors at Gilead Sciences, Moderna and Olema Oncology. We look forward to Sandra’s contributions to Foresight as we realize our vision for improved patient care.”ĭr. ![]() Additionally, Sandra’s first-hand experience in developing treatments for B cell lymphoma gives her a unique perspective that will inform development of our CLIA-validated B-cell lymphoma MRD platform. “We share a vision of improving cancer patient management by employing better diagnostic tools, as well as a shared belief that more sensitive MRD assays can improve clinical decision making. “Sandra has been at the forefront of biopharmaceutical innovation for many years, and brings significant experience and insight to our team,” said Jake Chabon, Ph.D., co-founder and Chief Executive Officer of Foresight Diagnostics. Horning has a keen interest in advancing minimal residual disease (MRD) adoption to accelerate the development of new drugs and clinical practice for the treatment and cure of cancers. Horning is an expert in the field of lymphoma therapy and is an accomplished Stanford University professor and biopharmaceutical industry executive. 19, 2022 (GLOBE NEWSWIRE) - Foresight Diagnostics today announced the appointment of Sandra Horning, M.D., FACP, FASCO, to its newly established Scientific Advisory Board (SAB). Accomplished academic and industry veteran with a successful record developing treatments for B cell lymphomaĪURORA, Colo., Jan.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |